no established social anxiety treatments. Social anxiety is associated with decreased quality of life (Hansson, 2006) , low self-esteem (Gumley et al., 2005) , and increased psychopathology (Vrbova et al., 2017) . Lysaker and Hammersley (2006) found that people with delusions and impairment in flexibility had the highest levels of social anxiety compared to those with fewer symptoms. Additionally, Lysaker et al. (2010) found that people with both high paranoia and theory of mind had higher social anxiety compared to those with lower levels of either paranoia or theory of mind. Taken together, this research suggests that symptoms may increase social anxiety, but other factors may inhibit their impact. The current study aims to add to this literature by exploring how different levels of hallucinations and self-esteem support affect social anxiety in SCZ. Methods: Outpatients with SCZ (N=50) participated in the current study. Participants were 76% male with a mean age of 42.50. Participants were African-American (n=27; 54%), Caucasian (n=11; 22%), multi-racial (n=5; 10%), Asian (n=4, 8%), or Hispanic (n=3; 6%). Social fear, social avoidance, and overall social anxiety was measured with the Liebowitz Social Anxiety Scale (LSAS; Liebowitz, 1987) . Self-esteem support (SeS) was measured with a subscale taken from the Interpersonal Support Evaluation List (ISEL; Cohen & Hoberman, 1983) . SeS is the appraisal of the self compared with others and other's opinions of the self. Hallucinations (HA) were scored with the observer-rated Scale for Assessment of Positive Symptoms (SAPS; Andreasen, 1983) . Participants were classified as having hallucinations if their SAPS global hallucinations were rated moderate to severe. This was chosen a priori as it reflects a level of clear hallucinations that may bother the person to some extent, as defined within the SAPS. Participants were classified as having either high or low SeS based on a mean split of the distribution of scores. Once participants were classified, we planned to compare groups on levels of social anxiety. This method was modified from previous research reporting similar groupings of symptoms and their relationship to social anxiety (Lysaker & Hammersley, 2006) . Results: Four groups resulted after including the dichotomized variables with the following proportions: low SeS/no HA (n=6; 12.5%), low SeS/HA (n=11, 22.9%), high SeS/no HA (n=13; 27.1%), and high SeS/HA (n=18, 37.5%). A one-way ANOVA was conducted to analyze the differences between groups. Post-Hoc analyses revealed the following differences. The HA/low SeS group had higher social anxiety than in the no HA/high SeS group (p=.030) and no HA/low SeS group (p=.039). The HA/low SeS group had higher social fear (p=.017) and social avoidance (p=.013) than in the no HA/high SeS group. There was a trending difference revealing that participants in the HA/low SeS group had higher social avoidance than in the HA/high SeS group (p=.056). There was a trending difference revealing that the HA/low SeS group had greater overall social anxiety than those in the HA/high SeS group (p=.064). Discussion: These results present preliminary findings on social anxiety in people with different levels of HA and SeS. We found that people with low SeS and HA had significantly higher levels of social anxiety, social fear, and social avoidance than participants with only one of neither of these symptoms. These results will be discussed further to highlight implications to treatment and comorbidities in SCZ. Background: Acute cannabis use stimulates appetite, while general population studies suggest that chronic use is associated with reduced risk of obesity and other cardiometabolic risk factors. Methods: In this study, we investigated changes in body mass index (BMI), fasting blood glucose and lipids, and rates of metabolic syndrome risk factors in cannabis users vs. non-users in 109 minimally treated patients with first-episode schizophrenia, schizophreniform or schizo-affective disorder who were treated according to a standardized treatment regime with depot antipsychotic medication over 12 months. Participants underwent repeated urine toxicology tests for cannabis and those testing positive at any time during the study (n=40), were compared with those who tested negative at all time points (n=69). Results: There was a significant group*time interaction effect (p=0.002) with the cannabis negative group showing a greater increase in BMI than the cannabis positive group, after adjusting for age, sex, methamphetamine use and modal dose of antipsychotic. There were no group*time interaction effects for fasting blood glucose or lipids. Post hoc tests indicated significant increases in fasting blood glucose and triglycerides and a decrease in high-density lipoprotein cholesterol for the cannabis negative group, with no significant changes in the cannabis positive group. Rates of metabolic syndrome did not differ significantly between groups. However, more cannabis negative patients had elevated waist-circumference at endpoint (p=0.003). Discussion: Although other indirect effects such as dietary neglect and smoking may be contributory and could explain our findings, it may be that chronic cannabis use directly suppresses appetite, thereby preventing weight gain in users. 
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S101. CLINICAL FACTORS ASSOCIATED WITH CANNABIS USE IN A CHILEAN SAMPLE OF FIRST EPISODE PSYCHOSIS PATIENTS
J. Horwitz Psychiatric Institute
Background: Cannabis has been associated with higher risk to develop psychosis and worse long-term outcomes. Cannabis use in 2016 is estimated to be 11.3% in Chile in 2016 (SENDA 2016). As in many other countries, cannabis use has steadily increased during last 20 years, across all socioeconomic groups, but especially in men and in the group aged 12 to 25 years old. At the same time, 5.7% subjects declared using high potency cannabis. We here examined the frequency of cannabis use in patients with a first episode psychosis in Chile. We also sought to identify etiologic factors associated with cannabis use, as well as its impact on clinical and functional status. Methods: We performed a cross-sectional study on patients from an outpatient Early Intervention in Psychosis unit in Chile. Data included sociodemographic characteristics, cannabis and other substance use, and standardized clinical and functional status. FAST (Functional Assessment Short Test), SS-DSM5 (Symptom Severity Scale of the DSM5 for Schizophrenia), CUPIT (Cannabis use Problem Identification Scale) and MG (Morinsky Green Adherence Questionnaire) were applied to the participants. Results: We included 80 patients, of which 23.8% used cannabis during the previous year. 47.3% of cannabis users had used cannabis with high THC concentration. 63.2% of consumers had a moderate-high score in the CUPIT scale, indicating a high prevalence of risk consumption and use disorder. Regarding variables related with cannabis use, correlation analysis showed a significant relationship with alcohol use (p<0.001), drug use (p<0.001) and duration of untreated psychosis (p=0.039, all corrected for multiple analysis.). Multivariate regression analyses including these variables along with gender and age, only showed relation with drug use (p=0.031, OR 7.94 (1.21-51.91). Regarding cannabis use and clinical and functional outcomes, correlation analysis showed association with adherence problems as reported by physician (p= 0.026) and the Morinsky Green Adherence Questionnaire (p= 0.031). Results showed an OR of 5.23 (1.38-19.76) for adherence problems and OR 0.2 (0.05-0.75) for Morinsky Green Adherence Questionnaire reporting good adherence. There was no effect in treatment resistance, FAST score, SS-DSM5 global, cognitive or negative score. Discussion: The percentage of cannabis use in this first episode psychosis sample is high, with a large subgroup using high potency THC cannabis. Cannabis use was associated to other drug use and to treatment adherence problems reported by physician and patient. This shows the importance of substance use treatment in first episode programs.
